KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Construction in Progress (2010 - 2021)

Johnson & Johnson recorded quarterly Construction in Progress of $4.3 billion in Q1 2021, up 18.67% quarter-over-quarter from $3.6 billion in Q4 2019, and up 18.67% year-over-year from $3.6 billion in Q1 2020.

Johnson & Johnson's Construction in Progress history runs 10 years deep, the most recent figure standing at $4.3 billion for Q1 2021.

  • In Q1 2021, Construction in Progress rose 18.67% year-over-year to $4.3 billion; the TTM figure through Jan 2021 stood at $4.3 billion (up 18.67% YoY), while the FY2021 annual figure was $4.3 billion, up 18.67% from the prior year.
  • Construction in Progress came in at $4.3 billion for Q1 2021 at Johnson & Johnson, up from $3.6 billion in the prior quarter.
  • In the past five years, Construction in Progress ranged from a high of $4.3 billion in Q1 2021 to a low of $3.4 billion in Q1 2017.
  • A 4-year average of $3.7 billion and a median of $3.6 billion in 2019 frame the typical range for Construction in Progress.
  • Across the five-year window, Construction in Progress dropped 6.17% in 2019 and gained 18.67% in 2021, its largest moves.
  • Johnson & Johnson's Construction in Progress stood at $3.4 billion in 2017, then advanced by 12.41% to $3.9 billion in 2018, then decreased by 6.17% to $3.6 billion in 2019, then climbed by 18.67% to $4.3 billion in 2021.
  • According to Business Quant data, Construction in Progress over the past three periods registered $4.3 billion, $3.6 billion, and $3.9 billion for Q1 2021, Q4 2019, and Q4 2018 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 1.54 Bn
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Jan 3, 2021 4.32 Bn
Dec 29, 2019 3.64 Bn
Dec 30, 2018 3.88 Bn
Dec 31, 2017 3.45 Bn
Jan 1, 2017 3.35 Bn
Jan 3, 2016 3.53 Bn
Dec 28, 2014 3.60 Bn
Dec 29, 2013 3.30 Bn
Dec 30, 2012 2.74 Bn
Jan 1, 2012 2.50 Bn
Jan 2, 2011 2.58 Bn
Jan 3, 2010 2.52 Bn